For anyone in Sé searching for CJC-1295, the key fact to understand is that this compound is available only through an online research supply market. This matters because CJC-1295 quality differs enormously across the market — from analytically confirmed high-purity product to mislabeled or underdosed compounds — and the vendor is the entire quality system. The primary quality indicators for CJC-1295 are HPLC purity ≥98%, molecular identity confirmed by mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. Use this guide to verify vendor quality systematically — the framework here work regardless of your location.
How CJC-1295 Works — Mechanisms & Research
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Sé researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Sourcing Research-Grade CJC-1295
The first step for any Sé researcher sourcing CJC-1295 is finding vendors with verified community track records — commercial rankings reflect SEO budgets rather than product quality. When reviewing a CJC-1295 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are below the threshold for research use. Warning signs in CJC-1295 vendor evaluation: prices significantly below market average, unclear production details, no community presence, and COAs that omit endotoxin testing. Hold lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the amount needed for the near-term protocol and return unused portion to the freezer.
Order CJC-1295 — ships to Sé
COA-verified · International tracking · Research grade
CJC-1295 operates beyond the scope of approved drug regulation — researchers should understand that the known safety profile is based on preclinical evidence rather than regulated clinical data. Storage requirements for CJC-1295: lyophilised powder at −20°C, reconstituted solution stored refrigerated at 2-8°C and finished within 30 days of reconstitution; reconstitute only with bacteriostatic water. The most significant preventable safety hazard in CJC-1295 research is bacterial endotoxin from low-quality material — a confirmed endotoxin test result in the lot-matched COA is the key safeguard. The research literature on CJC-1295 should be read critically before beginning any research — study methodologies, dosing, and endpoints vary significantly and results do not always generalise across models.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
